ArticleImmunity2013
Instant recall: a key role for effector-phenotype CD8⁺ memory T cells in immune protection.
Article in Immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Immune checkpoint targeting TIGIT in hepatocellular carcinoma.American journal of translational research · 2020Review
- mTOR Modulates CD8+ T Cell Differentiation in Mice with Invasive Pulmonary Aspergillosis.Open life sciences · 2018Article
- Role of Triggering Receptor Expressed on Myeloid Cell-1 Expression in Mammalian Target of Rapamycin Modulation of CD8Chinese medical journal · 2017Article
- IL-12 Influence mTOR to Modulate CD8International journal of medical sciences · 2017Article
- Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus.Scientific reports · 2016Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Immunity, Olson et al. (2013) demonstrate that circulating CD8⁺ memory T cells with an effector-like phenotype, previously thought to be mostly senescent, provide robust protection from a secondary pathogen challenge despite their poor secondary proliferative response.
Indexed as
Identifiers
23809159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.